| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cerebral Amyloid Angiopathy | 87 | 2023 | 859 | 17.160 |
Why?
|
| Cerebral Hemorrhage | 144 | 2023 | 2647 | 13.700 |
Why?
|
| Siderosis | 11 | 2023 | 102 | 3.700 |
Why?
|
| Hemosiderosis | 6 | 2020 | 71 | 2.300 |
Why?
|
| Stroke | 45 | 2023 | 9981 | 2.200 |
Why?
|
| CADASIL | 15 | 2020 | 84 | 1.990 |
Why?
|
| Cerebrovascular Disorders | 11 | 2023 | 1504 | 1.980 |
Why?
|
| Intracranial Hemorrhages | 12 | 2020 | 855 | 1.850 |
Why?
|
| Magnetic Resonance Imaging | 115 | 2023 | 35421 | 1.850 |
Why?
|
| Brain | 51 | 2023 | 26385 | 1.850 |
Why?
|
| Subarachnoid Hemorrhage | 6 | 2021 | 1018 | 1.700 |
Why?
|
| Hematoma | 19 | 2023 | 758 | 1.620 |
Why?
|
| Cerebral Cortex | 22 | 2019 | 5708 | 1.580 |
Why?
|
| Dementia | 12 | 2022 | 2518 | 1.450 |
Why?
|
| Cognition Disorders | 20 | 2020 | 4043 | 1.430 |
Why?
|
| Amyloid | 7 | 2022 | 795 | 1.280 |
Why?
|
| Apolipoprotein E4 | 11 | 2022 | 668 | 1.220 |
Why?
|
| Aged | 175 | 2023 | 163280 | 1.150 |
Why?
|
| Dementia, Vascular | 4 | 2015 | 128 | 1.130 |
Why?
|
| Brain Infarction | 7 | 2021 | 299 | 1.120 |
Why?
|
| Arteriolosclerosis | 2 | 2023 | 21 | 1.100 |
Why?
|
| Leukoencephalopathies | 4 | 2022 | 238 | 1.050 |
Why?
|
| Apolipoprotein E2 | 7 | 2019 | 127 | 1.020 |
Why?
|
| Cerebral Amyloid Angiopathy, Familial | 2 | 2023 | 53 | 1.000 |
Why?
|
| Cerebellar Diseases | 4 | 2021 | 226 | 0.990 |
Why?
|
| Amyloid beta-Peptides | 15 | 2023 | 3587 | 0.980 |
Why?
|
| Alzheimer Disease | 14 | 2023 | 8037 | 0.930 |
Why?
|
| Apolipoproteins E | 10 | 2022 | 1438 | 0.920 |
Why?
|
| Aged, 80 and over | 94 | 2023 | 57776 | 0.920 |
Why?
|
| Cognition | 11 | 2023 | 6770 | 0.920 |
Why?
|
| Anticoagulants | 13 | 2023 | 4599 | 0.850 |
Why?
|
| Apathy | 1 | 2023 | 96 | 0.830 |
Why?
|
| Hypertension | 23 | 2023 | 8480 | 0.830 |
Why?
|
| Male | 188 | 2023 | 350118 | 0.830 |
Why?
|
| Female | 189 | 2023 | 380194 | 0.800 |
Why?
|
| Humans | 263 | 2023 | 744343 | 0.800 |
Why?
|
| tau Proteins | 4 | 2021 | 1868 | 0.780 |
Why?
|
| Intracranial Hemorrhage, Hypertensive | 2 | 2017 | 20 | 0.740 |
Why?
|
| Cerebral Angiography | 14 | 2021 | 1285 | 0.740 |
Why?
|
| Cohort Studies | 58 | 2022 | 40561 | 0.730 |
Why?
|
| Hematoma, Subdural, Intracranial | 2 | 2017 | 33 | 0.730 |
Why?
|
| Memory Disorders | 2 | 2021 | 1184 | 0.730 |
Why?
|
| Brain Ischemia | 12 | 2021 | 3265 | 0.680 |
Why?
|
| Aniline Compounds | 6 | 2022 | 986 | 0.620 |
Why?
|
| Ethylene Glycols | 1 | 2018 | 156 | 0.620 |
Why?
|
| Middle Aged | 129 | 2023 | 213383 | 0.610 |
Why?
|
| Diffusion Tensor Imaging | 8 | 2023 | 2305 | 0.580 |
Why?
|
| Recurrence | 17 | 2021 | 8340 | 0.580 |
Why?
|
| Image Processing, Computer-Assisted | 24 | 2018 | 8949 | 0.570 |
Why?
|
| Longitudinal Studies | 23 | 2022 | 13989 | 0.520 |
Why?
|
| Perceptual Disorders | 1 | 2017 | 196 | 0.510 |
Why?
|
| Cerebral Infarction | 7 | 2022 | 1011 | 0.500 |
Why?
|
| Prospective Studies | 45 | 2023 | 53288 | 0.490 |
Why?
|
| Guidelines as Topic | 2 | 2020 | 1405 | 0.490 |
Why?
|
| Motor Vehicles | 1 | 2016 | 268 | 0.490 |
Why?
|
| Tomography, X-Ray Computed | 28 | 2023 | 20129 | 0.480 |
Why?
|
| Blood Pressure | 12 | 2022 | 8554 | 0.480 |
Why?
|
| Executive Function | 6 | 2023 | 1364 | 0.470 |
Why?
|
| Ischemic Attack, Transient | 3 | 2019 | 935 | 0.470 |
Why?
|
| Warfarin | 8 | 2017 | 1496 | 0.470 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 857 | 0.470 |
Why?
|
| Leukoaraiosis | 3 | 2022 | 120 | 0.430 |
Why?
|
| Neuropsychological Tests | 13 | 2022 | 6993 | 0.430 |
Why?
|
| Age Distribution | 3 | 2016 | 2902 | 0.420 |
Why?
|
| Gait | 2 | 2022 | 793 | 0.420 |
Why?
|
| Peptide Fragments | 4 | 2019 | 5097 | 0.400 |
Why?
|
| Tissue Plasminogen Activator | 6 | 2020 | 1261 | 0.400 |
Why?
|
| Housing | 1 | 2016 | 664 | 0.400 |
Why?
|
| Aging | 9 | 2022 | 8664 | 0.390 |
Why?
|
| Disease Progression | 20 | 2021 | 13284 | 0.370 |
Why?
|
| Retrospective Studies | 53 | 2023 | 77449 | 0.370 |
Why?
|
| Risk Factors | 42 | 2022 | 72290 | 0.370 |
Why?
|
| Cerebral Arteries | 6 | 2017 | 494 | 0.360 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 1076 | 0.350 |
Why?
|
| Fibrinolytic Agents | 6 | 2020 | 2158 | 0.350 |
Why?
|
| Severity of Illness Index | 14 | 2021 | 15540 | 0.350 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 8 | 2023 | 2737 | 0.350 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2012 | 231 | 0.350 |
Why?
|
| Polysomnography | 1 | 2015 | 1776 | 0.330 |
Why?
|
| Predictive Value of Tests | 15 | 2020 | 15076 | 0.320 |
Why?
|
| Health Policy | 1 | 2020 | 2661 | 0.320 |
Why?
|
| Visual Perception | 1 | 2017 | 1420 | 0.310 |
Why?
|
| Memory | 3 | 2016 | 2174 | 0.300 |
Why?
|
| Atrophy | 7 | 2020 | 1583 | 0.300 |
Why?
|
| Public Health | 1 | 2020 | 2603 | 0.300 |
Why?
|
| Telemedicine | 7 | 2021 | 2872 | 0.300 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 1432 | 0.300 |
Why?
|
| Brain Diseases | 3 | 2022 | 1563 | 0.300 |
Why?
|
| Intracranial Arteriosclerosis | 2 | 2019 | 138 | 0.290 |
Why?
|
| Postural Balance | 1 | 2012 | 620 | 0.290 |
Why?
|
| Vitamin K | 3 | 2017 | 295 | 0.290 |
Why?
|
| Multivariate Analysis | 11 | 2018 | 12245 | 0.290 |
Why?
|
| Prevalence | 10 | 2021 | 15226 | 0.280 |
Why?
|
| Receptors, Formyl Peptide | 1 | 2007 | 145 | 0.280 |
Why?
|
| Patient Transfer | 5 | 2019 | 761 | 0.280 |
Why?
|
| Positron-Emission Tomography | 11 | 2022 | 6234 | 0.280 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 2291 | 0.270 |
Why?
|
| Tomography Scanners, X-Ray Computed | 2 | 2016 | 168 | 0.260 |
Why?
|
| Homocysteine | 1 | 2009 | 647 | 0.260 |
Why?
|
| Odds Ratio | 8 | 2019 | 9849 | 0.260 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2019 | 17446 | 0.260 |
Why?
|
| DNA Damage | 4 | 2000 | 2432 | 0.250 |
Why?
|
| Statistics, Nonparametric | 8 | 2017 | 2886 | 0.250 |
Why?
|
| Mutagenesis | 2 | 1999 | 1266 | 0.250 |
Why?
|
| Vascular Diseases | 2 | 2015 | 1161 | 0.250 |
Why?
|
| Image Interpretation, Computer-Assisted | 5 | 2014 | 3327 | 0.250 |
Why?
|
| Particulate Matter | 1 | 2016 | 2530 | 0.250 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 5137 | 0.240 |
Why?
|
| Geriatric Assessment | 1 | 2012 | 1372 | 0.240 |
Why?
|
| Cross-Sectional Studies | 13 | 2021 | 25043 | 0.240 |
Why?
|
| Seizures | 1 | 2016 | 2859 | 0.230 |
Why?
|
| Sleep | 2 | 2020 | 4623 | 0.230 |
Why?
|
| Risk | 9 | 2019 | 9687 | 0.230 |
Why?
|
| Follow-Up Studies | 17 | 2021 | 39050 | 0.230 |
Why?
|
| Proportional Hazards Models | 7 | 2017 | 12354 | 0.220 |
Why?
|
| Leukoencephalitis, Acute Hemorrhagic | 1 | 2022 | 16 | 0.220 |
Why?
|
| Escherichia coli | 4 | 2000 | 4217 | 0.220 |
Why?
|
| Air Pollution | 1 | 2016 | 2286 | 0.210 |
Why?
|
| Microvessels | 2 | 2017 | 544 | 0.210 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2021 | 941 | 0.210 |
Why?
|
| Organ Size | 3 | 2017 | 2252 | 0.210 |
Why?
|
| Comorbidity | 8 | 2023 | 10388 | 0.210 |
Why?
|
| Logistic Models | 10 | 2021 | 13408 | 0.210 |
Why?
|
| Uracil | 3 | 2000 | 165 | 0.210 |
Why?
|
| Neural Pathways | 4 | 2017 | 2972 | 0.200 |
Why?
|
| Environmental Exposure | 1 | 2016 | 4234 | 0.200 |
Why?
|
| Linear Models | 6 | 2019 | 5952 | 0.200 |
Why?
|
| Case-Control Studies | 13 | 2019 | 21746 | 0.200 |
Why?
|
| Time Factors | 16 | 2021 | 40075 | 0.200 |
Why?
|
| Patient Admission | 2 | 2019 | 1380 | 0.190 |
Why?
|
| Remote Consultation | 3 | 2020 | 238 | 0.190 |
Why?
|
| Prognosis | 16 | 2023 | 29063 | 0.190 |
Why?
|
| Nerve Fibers, Myelinated | 4 | 2019 | 957 | 0.190 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2017 | 3068 | 0.180 |
Why?
|
| Amyloidogenic Proteins | 2 | 2022 | 152 | 0.180 |
Why?
|
| Vitamins | 1 | 2009 | 1622 | 0.180 |
Why?
|
| DNA-Directed RNA Polymerases | 2 | 1999 | 371 | 0.180 |
Why?
|
| Netherlands | 3 | 2020 | 2170 | 0.170 |
Why?
|
| Apolipoprotein E3 | 1 | 2019 | 97 | 0.170 |
Why?
|
| Age Factors | 7 | 2019 | 18370 | 0.170 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2021 | 145 | 0.170 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 2513 | 0.170 |
Why?
|
| Transcription, Genetic | 5 | 2010 | 7722 | 0.170 |
Why?
|
| Neurofibrillary Tangles | 1 | 2021 | 439 | 0.160 |
Why?
|
| Genetic Variation | 5 | 2015 | 6544 | 0.160 |
Why?
|
| Policy | 1 | 2022 | 508 | 0.160 |
Why?
|
| Cerebral Ventricles | 2 | 2019 | 544 | 0.160 |
Why?
|
| Internship and Residency | 1 | 2018 | 5788 | 0.160 |
Why?
|
| Genotype | 12 | 2016 | 12951 | 0.150 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2019 | 189 | 0.150 |
Why?
|
| Cost of Illness | 2 | 2017 | 1859 | 0.150 |
Why?
|
| Amyloidosis | 2 | 2022 | 795 | 0.150 |
Why?
|
| Chaplaincy Service, Hospital | 1 | 2017 | 22 | 0.150 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2014 | 3255 | 0.150 |
Why?
|
| Thrombolytic Therapy | 4 | 2020 | 2161 | 0.150 |
Why?
|
| Atrial Fibrillation | 3 | 2023 | 5034 | 0.150 |
Why?
|
| Subarachnoid Space | 1 | 2017 | 79 | 0.150 |
Why?
|
| Intracranial Embolism | 1 | 2018 | 202 | 0.150 |
Why?
|
| Incidence | 8 | 2021 | 20947 | 0.140 |
Why?
|
| Collateral Circulation | 1 | 2017 | 287 | 0.140 |
Why?
|
| Mind-Body Therapies | 1 | 2019 | 247 | 0.140 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2007 | 1632 | 0.140 |
Why?
|
| Hypoalbuminemia | 1 | 2017 | 87 | 0.140 |
Why?
|
| Pastoral Care | 1 | 2017 | 73 | 0.140 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2016 | 110 | 0.130 |
Why?
|
| Genome-Wide Association Study | 7 | 2023 | 12261 | 0.130 |
Why?
|
| Critical Care | 2 | 2019 | 2647 | 0.130 |
Why?
|
| International Normalized Ratio | 1 | 2017 | 367 | 0.130 |
Why?
|
| Fluorine Radioisotopes | 1 | 2018 | 442 | 0.130 |
Why?
|
| Hypocalcemia | 1 | 2016 | 191 | 0.130 |
Why?
|
| Adult | 34 | 2022 | 214055 | 0.130 |
Why?
|
| Hippocampus | 2 | 2023 | 3675 | 0.130 |
Why?
|
| Pons | 1 | 2016 | 245 | 0.130 |
Why?
|
| Expert Testimony | 1 | 2017 | 356 | 0.130 |
Why?
|
| Brain Stem Hemorrhage, Traumatic | 1 | 2014 | 13 | 0.130 |
Why?
|
| Academic Medical Centers | 3 | 2020 | 2759 | 0.130 |
Why?
|
| Neurosciences | 1 | 2019 | 348 | 0.120 |
Why?
|
| Lymphopenia | 1 | 2017 | 285 | 0.120 |
Why?
|
| Thalamus | 3 | 2013 | 1023 | 0.120 |
Why?
|
| Blood Vessels | 2 | 2011 | 1125 | 0.120 |
Why?
|
| Peroxidase | 1 | 2017 | 611 | 0.120 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2008 | 4042 | 0.120 |
Why?
|
| Contrast Media | 3 | 2022 | 5300 | 0.120 |
Why?
|
| Drainage | 1 | 2020 | 1142 | 0.120 |
Why?
|
| Depression | 3 | 2022 | 7766 | 0.120 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 401 | 0.120 |
Why?
|
| Urinary Tract Infections | 2 | 2017 | 788 | 0.120 |
Why?
|
| Treatment Outcome | 19 | 2023 | 63114 | 0.120 |
Why?
|
| Plasma | 1 | 2017 | 575 | 0.120 |
Why?
|
| Serum Albumin | 1 | 2017 | 676 | 0.120 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2017 | 475 | 0.120 |
Why?
|
| Apoptosis | 2 | 2007 | 9727 | 0.110 |
Why?
|
| Statistics as Topic | 3 | 2016 | 2373 | 0.110 |
Why?
|
| American Heart Association | 1 | 2017 | 1056 | 0.110 |
Why?
|
| Antihypertensive Agents | 2 | 2020 | 2046 | 0.110 |
Why?
|
| Alleles | 3 | 2013 | 6933 | 0.110 |
Why?
|
| Hematoma, Epidural, Cranial | 1 | 2013 | 60 | 0.110 |
Why?
|
| Temporal Lobe | 2 | 2019 | 1670 | 0.110 |
Why?
|
| Radiography | 5 | 2016 | 7023 | 0.110 |
Why?
|
| Phospholipases A2 | 1 | 2012 | 203 | 0.110 |
Why?
|
| Risk Assessment | 8 | 2020 | 23338 | 0.110 |
Why?
|
| Thrombectomy | 1 | 2017 | 680 | 0.100 |
Why?
|
| Thiazoles | 4 | 2019 | 1483 | 0.100 |
Why?
|
| Leukocyte Count | 1 | 2016 | 1588 | 0.100 |
Why?
|
| Massachusetts | 3 | 2020 | 8663 | 0.100 |
Why?
|
| Radiology, Interventional | 2 | 2007 | 460 | 0.100 |
Why?
|
| Neurosurgical Procedures | 2 | 2020 | 2002 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 6538 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2014 | 658 | 0.100 |
Why?
|
| Mobility Limitation | 1 | 2015 | 409 | 0.100 |
Why?
|
| Basal Ganglia | 3 | 2013 | 546 | 0.100 |
Why?
|
| Medulloblastoma | 1 | 2017 | 683 | 0.100 |
Why?
|
| Sex Characteristics | 2 | 2023 | 2585 | 0.100 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 681 | 0.100 |
Why?
|
| Social Behavior | 1 | 2018 | 1127 | 0.100 |
Why?
|
| Brachial Plexus Neuropathies | 1 | 2012 | 122 | 0.100 |
Why?
|
| Myocardial Infarction | 2 | 2022 | 11727 | 0.100 |
Why?
|
| Brachial Plexus | 1 | 2012 | 163 | 0.090 |
Why?
|
| Postoperative Hemorrhage | 1 | 2014 | 413 | 0.090 |
Why?
|
| Oxidative Phosphorylation | 1 | 2013 | 481 | 0.090 |
Why?
|
| Axons | 1 | 2019 | 1684 | 0.090 |
Why?
|
| Microcirculation | 1 | 2015 | 1286 | 0.090 |
Why?
|
| Glasgow Coma Scale | 3 | 2019 | 570 | 0.090 |
Why?
|
| Triage | 1 | 2017 | 976 | 0.090 |
Why?
|
| Arteries | 2 | 2022 | 1119 | 0.090 |
Why?
|
| Plaque, Amyloid | 2 | 2011 | 729 | 0.090 |
Why?
|
| Blood Loss, Surgical | 1 | 2014 | 662 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 2 | 1999 | 5867 | 0.090 |
Why?
|
| Telephone | 2 | 2012 | 617 | 0.090 |
Why?
|
| Regression Analysis | 2 | 2017 | 6459 | 0.090 |
Why?
|
| Reproducibility of Results | 9 | 2019 | 19905 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 2208 | 0.090 |
Why?
|
| Administration, Oral | 3 | 2023 | 3913 | 0.090 |
Why?
|
| Radiation Injuries | 1 | 2017 | 1180 | 0.090 |
Why?
|
| Calcium | 2 | 2016 | 5756 | 0.090 |
Why?
|
| Diagnosis, Differential | 5 | 2016 | 12959 | 0.080 |
Why?
|
| Templates, Genetic | 2 | 1999 | 211 | 0.080 |
Why?
|
| Delayed Diagnosis | 1 | 2012 | 441 | 0.080 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2018 | 2016 | 0.080 |
Why?
|
| Registries | 4 | 2019 | 8089 | 0.080 |
Why?
|
| Pyridoxine | 1 | 2009 | 102 | 0.080 |
Why?
|
| Genes | 1 | 2013 | 1893 | 0.080 |
Why?
|
| United States | 9 | 2022 | 69872 | 0.080 |
Why?
|
| Sensitivity and Specificity | 7 | 2019 | 14722 | 0.080 |
Why?
|
| Ischemia | 1 | 2017 | 1907 | 0.080 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2007 | 1018 | 0.080 |
Why?
|
| Pneumonia | 2 | 2017 | 2133 | 0.080 |
Why?
|
| Image Enhancement | 3 | 2008 | 2921 | 0.080 |
Why?
|
| Triglycerides | 1 | 2016 | 2454 | 0.080 |
Why?
|
| Carotid Artery, Internal, Dissection | 1 | 2008 | 45 | 0.080 |
Why?
|
| Vertebral Artery Dissection | 1 | 2008 | 48 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 9959 | 0.080 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2009 | 187 | 0.080 |
Why?
|
| Hematoma, Subdural | 1 | 2009 | 126 | 0.080 |
Why?
|
| Central Nervous System | 1 | 2015 | 1357 | 0.080 |
Why?
|
| Radiographic Image Enhancement | 2 | 2017 | 885 | 0.080 |
Why?
|
| Osmolar Concentration | 1 | 2009 | 683 | 0.080 |
Why?
|
| Disability Evaluation | 2 | 2023 | 1827 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 2 | 2022 | 9274 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 4149 | 0.080 |
Why?
|
| New England | 2 | 2021 | 1022 | 0.080 |
Why?
|
| Hospital Mortality | 3 | 2016 | 5317 | 0.070 |
Why?
|
| Electromyography | 1 | 2012 | 1379 | 0.070 |
Why?
|
| France | 1 | 2008 | 517 | 0.070 |
Why?
|
| Pandemics | 3 | 2023 | 8388 | 0.070 |
Why?
|
| Cerebrovascular Circulation | 2 | 2020 | 2731 | 0.070 |
Why?
|
| Neurons | 1 | 2006 | 9338 | 0.070 |
Why?
|
| Cholesterol | 1 | 2016 | 2917 | 0.070 |
Why?
|
| Hypochlorous Acid | 1 | 2006 | 15 | 0.070 |
Why?
|
| RNA, Bacterial | 2 | 1999 | 390 | 0.070 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 2007 | 222 | 0.070 |
Why?
|
| Accidents, Traffic | 1 | 2012 | 819 | 0.070 |
Why?
|
| Receptors, Lipoxin | 1 | 2007 | 84 | 0.070 |
Why?
|
| Respiratory Mucosa | 1 | 2010 | 427 | 0.070 |
Why?
|
| Vitamin B Complex | 1 | 2009 | 288 | 0.070 |
Why?
|
| Germany | 1 | 2008 | 862 | 0.070 |
Why?
|
| Intensive Care Units | 1 | 2019 | 3679 | 0.070 |
Why?
|
| Models, Cardiovascular | 1 | 2011 | 996 | 0.070 |
Why?
|
| Vitamin B 12 | 1 | 2009 | 527 | 0.070 |
Why?
|
| Secretory Vesicles | 1 | 2006 | 124 | 0.070 |
Why?
|
| Spinal Cord Injuries | 1 | 2013 | 931 | 0.070 |
Why?
|
| Phagosomes | 1 | 2006 | 193 | 0.060 |
Why?
|
| Biopsy, Needle | 2 | 2007 | 1641 | 0.060 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 3508 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 3843 | 0.060 |
Why?
|
| Phenotype | 4 | 2015 | 16365 | 0.060 |
Why?
|
| Residence Characteristics | 1 | 2014 | 2050 | 0.060 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2013 | 1442 | 0.060 |
Why?
|
| Biopsy | 1 | 2016 | 6756 | 0.060 |
Why?
|
| Nerve Net | 1 | 2016 | 2174 | 0.060 |
Why?
|
| Magnetics | 1 | 2007 | 606 | 0.060 |
Why?
|
| Neurodegenerative Diseases | 1 | 2013 | 1061 | 0.060 |
Why?
|
| Electromagnetic Phenomena | 1 | 2005 | 161 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 1956 | 0.060 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 1622 | 0.060 |
Why?
|
| Blood Pressure Determination | 2 | 2019 | 634 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 1999 | 13033 | 0.060 |
Why?
|
| Accidental Falls | 1 | 2012 | 1062 | 0.060 |
Why?
|
| Chemotaxis | 1 | 2007 | 607 | 0.060 |
Why?
|
| Catheter Ablation | 2 | 2007 | 2758 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2017 | 8324 | 0.060 |
Why?
|
| Survival Rate | 5 | 2021 | 12788 | 0.060 |
Why?
|
| Ethanol | 1 | 2010 | 1342 | 0.060 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2006 | 437 | 0.060 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2019 | 3658 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2010 | 4217 | 0.060 |
Why?
|
| Anisotropy | 2 | 2019 | 1265 | 0.060 |
Why?
|
| Subtraction Technique | 1 | 2006 | 525 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 7279 | 0.060 |
Why?
|
| Patient Discharge | 3 | 2023 | 3313 | 0.050 |
Why?
|
| Sepsis | 1 | 2017 | 2593 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2009 | 2618 | 0.050 |
Why?
|
| Anticonvulsants | 1 | 2012 | 1916 | 0.050 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2007 | 849 | 0.050 |
Why?
|
| Air Pollutants | 1 | 2016 | 2817 | 0.050 |
Why?
|
| Folic Acid | 1 | 2009 | 1300 | 0.050 |
Why?
|
| Vaccines, Inactivated | 1 | 2022 | 184 | 0.050 |
Why?
|
| Receptors, Notch | 1 | 2006 | 739 | 0.050 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 2703 | 0.050 |
Why?
|
| Postpartum Period | 1 | 2008 | 1086 | 0.050 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2022 | 165 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2009 | 3002 | 0.050 |
Why?
|
| Myelography | 1 | 2021 | 69 | 0.050 |
Why?
|
| Hong Kong | 1 | 2021 | 148 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2010 | 2969 | 0.050 |
Why?
|
| Mutagenicity Tests | 1 | 2000 | 46 | 0.050 |
Why?
|
| Survivors | 2 | 2015 | 2291 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 1889 | 0.050 |
Why?
|
| Single-Blind Method | 2 | 2015 | 1590 | 0.050 |
Why?
|
| Brain Stem | 1 | 2006 | 846 | 0.050 |
Why?
|
| Antipsychotic Agents | 1 | 2014 | 3057 | 0.050 |
Why?
|
| Infarction | 1 | 2022 | 244 | 0.050 |
Why?
|
| Spin Labels | 1 | 2022 | 332 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2019 | 12026 | 0.050 |
Why?
|
| Dilatation | 1 | 2021 | 291 | 0.050 |
Why?
|
| Medical Records | 1 | 2006 | 1413 | 0.050 |
Why?
|
| Cell Adhesion | 1 | 2007 | 3144 | 0.040 |
Why?
|
| Antidepressive Agents | 2 | 2022 | 2838 | 0.040 |
Why?
|
| Hinduism | 1 | 2019 | 14 | 0.040 |
Why?
|
| Pattern Recognition, Automated | 1 | 2006 | 1005 | 0.040 |
Why?
|
| Off-Label Use | 1 | 2021 | 169 | 0.040 |
Why?
|
| Brain Injuries | 1 | 2011 | 2025 | 0.040 |
Why?
|
| Lipoproteins | 2 | 2015 | 878 | 0.040 |
Why?
|
| Colombia | 1 | 2020 | 258 | 0.040 |
Why?
|
| Neutrophils | 2 | 2016 | 3719 | 0.040 |
Why?
|
| Novobiocin | 1 | 1999 | 35 | 0.040 |
Why?
|
| Base Pair Mismatch | 1 | 1999 | 97 | 0.040 |
Why?
|
| Base Pairing | 1 | 1999 | 141 | 0.040 |
Why?
|
| Codon, Terminator | 1 | 1999 | 127 | 0.040 |
Why?
|
| Cardiovascular Diseases | 2 | 2019 | 15165 | 0.040 |
Why?
|
| Genes, Reporter | 2 | 2000 | 1547 | 0.040 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2007 | 1624 | 0.040 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2023 | 967 | 0.040 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2023 | 859 | 0.040 |
Why?
|
| Software | 3 | 2007 | 4443 | 0.040 |
Why?
|
| Molecular Chaperones | 1 | 2022 | 742 | 0.040 |
Why?
|
| Corpus Callosum | 1 | 2022 | 737 | 0.040 |
Why?
|
| Cystic Fibrosis | 1 | 2006 | 1177 | 0.040 |
Why?
|
| PubMed | 1 | 2018 | 123 | 0.040 |
Why?
|
| Entorhinal Cortex | 1 | 2019 | 272 | 0.040 |
Why?
|
| Heart Atria | 1 | 2023 | 1357 | 0.040 |
Why?
|
| Carbolines | 1 | 2019 | 265 | 0.040 |
Why?
|
| Luciferases | 1 | 1999 | 733 | 0.040 |
Why?
|
| Epilepsy | 1 | 2012 | 3310 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 18029 | 0.040 |
Why?
|
| Sex Factors | 3 | 2016 | 10397 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2013 | 2274 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2021 | 10252 | 0.040 |
Why?
|
| Nonlinear Dynamics | 1 | 2019 | 502 | 0.040 |
Why?
|
| India | 2 | 2013 | 2197 | 0.040 |
Why?
|
| Blood Component Transfusion | 1 | 2017 | 143 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 10943 | 0.030 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 1999 | 486 | 0.030 |
Why?
|
| Migraine Disorders | 1 | 2008 | 1620 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 6487 | 0.030 |
Why?
|
| Community Health Planning | 1 | 2016 | 165 | 0.030 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2016 | 82 | 0.030 |
Why?
|
| Europe | 1 | 2022 | 3339 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 8863 | 0.030 |
Why?
|
| Animals | 4 | 2015 | 168757 | 0.030 |
Why?
|
| Workflow | 1 | 2020 | 847 | 0.030 |
Why?
|
| Myocardial Ischemia | 1 | 2006 | 2148 | 0.030 |
Why?
|
| Leukocytosis | 1 | 2016 | 247 | 0.030 |
Why?
|
| Antifibrinolytic Agents | 1 | 2017 | 254 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 2021 | 1017 | 0.030 |
Why?
|
| Young Adult | 6 | 2018 | 56430 | 0.030 |
Why?
|
| Headache | 1 | 2022 | 1226 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2016 | 15519 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2007 | 5985 | 0.030 |
Why?
|
| Abbreviated Injury Scale | 1 | 2013 | 51 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 1999 | 1465 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 950 | 0.030 |
Why?
|
| Boston | 2 | 2017 | 9313 | 0.030 |
Why?
|
| DNA Primers | 1 | 1998 | 2892 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2022 | 2902 | 0.030 |
Why?
|
| Aftercare | 1 | 2020 | 866 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2011 | 12720 | 0.030 |
Why?
|
| Inflammation | 3 | 2020 | 10638 | 0.030 |
Why?
|
| Referral and Consultation | 2 | 2020 | 3528 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 1584 | 0.030 |
Why?
|
| Autopsy | 1 | 2016 | 1020 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2020 | 1504 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2022 | 3200 | 0.030 |
Why?
|
| Motorcycles | 1 | 2012 | 44 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2017 | 7729 | 0.030 |
Why?
|
| Quadriplegia | 1 | 2013 | 223 | 0.030 |
Why?
|
| Rehabilitation Centers | 1 | 2013 | 254 | 0.030 |
Why?
|
| Credentialing | 1 | 2012 | 126 | 0.030 |
Why?
|
| Acute Disease | 2 | 2012 | 7149 | 0.030 |
Why?
|
| Licensure | 1 | 2012 | 124 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 1999 | 2126 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2018 | 2539 | 0.020 |
Why?
|
| Online Systems | 1 | 2012 | 184 | 0.020 |
Why?
|
| Lung | 1 | 2010 | 9856 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2020 | 2488 | 0.020 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2016 | 1121 | 0.020 |
Why?
|
| Brain Mapping | 3 | 2012 | 6669 | 0.020 |
Why?
|
| Algorithms | 2 | 2008 | 13881 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2005 | 3507 | 0.020 |
Why?
|
| Computer Systems | 1 | 2012 | 483 | 0.020 |
Why?
|
| Trauma Severity Indices | 1 | 2012 | 481 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2010 | 12208 | 0.020 |
Why?
|
| Videoconferencing | 1 | 2012 | 195 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2016 | 1814 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2014 | 720 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2019 | 1580 | 0.020 |
Why?
|
| DNA Repair | 1 | 1999 | 2046 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2020 | 4199 | 0.020 |
Why?
|
| Subdural Space | 1 | 2009 | 32 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2012 | 1308 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2015 | 1530 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2022 | 6196 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 12072 | 0.020 |
Why?
|
| Arterioles | 1 | 2009 | 254 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2018 | 3420 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2018 | 2925 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 2031 | 0.020 |
Why?
|
| Glasgow Outcome Scale | 1 | 2008 | 109 | 0.020 |
Why?
|
| Adolescent | 4 | 2019 | 85781 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2014 | 2290 | 0.020 |
Why?
|
| Feasibility Studies | 2 | 2009 | 5078 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 940 | 0.020 |
Why?
|
| Child | 4 | 2019 | 77709 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 2013 | 975 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2010 | 651 | 0.020 |
Why?
|
| Base Sequence | 1 | 1998 | 12797 | 0.020 |
Why?
|
| Mutation | 2 | 2022 | 29786 | 0.020 |
Why?
|
| Occipital Lobe | 1 | 2008 | 379 | 0.020 |
Why?
|
| International Cooperation | 1 | 2013 | 1420 | 0.020 |
Why?
|
| Monocytes | 1 | 2016 | 2596 | 0.020 |
Why?
|
| Reimbursement Mechanisms | 1 | 2012 | 670 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2014 | 1774 | 0.020 |
Why?
|
| Models, Genetic | 2 | 2010 | 3494 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2013 | 1547 | 0.020 |
Why?
|
| Documentation | 1 | 2012 | 871 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 2019 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 6038 | 0.020 |
Why?
|
| HL-60 Cells | 1 | 2006 | 365 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2010 | 1344 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 6365 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2019 | 41006 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1998 | 18111 | 0.020 |
Why?
|
| Electronics, Medical | 1 | 2005 | 71 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2007 | 758 | 0.020 |
Why?
|
| Finite Element Analysis | 1 | 2007 | 431 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 2008 | 603 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2010 | 3588 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2010 | 1538 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2019 | 4445 | 0.010 |
Why?
|
| DNA | 2 | 2012 | 7301 | 0.010 |
Why?
|
| International Classification of Diseases | 1 | 2008 | 867 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2017 | 4371 | 0.010 |
Why?
|
| Needles | 1 | 2005 | 449 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 2716 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 7913 | 0.010 |
Why?
|
| Hypercholesterolemia | 1 | 2008 | 1151 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2008 | 1359 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 3920 | 0.010 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2008 | 1953 | 0.010 |
Why?
|
| Phagocytosis | 1 | 2006 | 1539 | 0.010 |
Why?
|
| Transformation, Genetic | 1 | 2000 | 192 | 0.010 |
Why?
|
| Insurance, Health | 1 | 2012 | 2494 | 0.010 |
Why?
|
| Catheterization | 1 | 2005 | 1470 | 0.010 |
Why?
|
| Angiography | 1 | 2005 | 1639 | 0.010 |
Why?
|
| User-Computer Interface | 1 | 2006 | 1431 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2014 | 5102 | 0.010 |
Why?
|
| Length of Stay | 1 | 2012 | 6309 | 0.010 |
Why?
|
| Infant | 1 | 2021 | 35136 | 0.010 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2006 | 1219 | 0.010 |
Why?
|
| Hospitals | 1 | 2012 | 3952 | 0.010 |
Why?
|
| Models, Animal | 1 | 2005 | 2171 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2006 | 1990 | 0.010 |
Why?
|
| Radiography, Interventional | 1 | 2005 | 1095 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 2005 | 2480 | 0.010 |
Why?
|
| Equipment Design | 1 | 2005 | 3582 | 0.010 |
Why?
|
| Medicare | 1 | 2014 | 6566 | 0.010 |
Why?
|
| Cell Line | 1 | 2010 | 15997 | 0.010 |
Why?
|
| Plasmids | 1 | 2000 | 2307 | 0.010 |
Why?
|
| Cytokines | 1 | 2010 | 7322 | 0.010 |
Why?
|
| Swine | 1 | 2005 | 5917 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 9438 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 16689 | 0.010 |
Why?
|
| Artificial Intelligence | 1 | 2006 | 2214 | 0.010 |
Why?
|
| Cell Division | 1 | 2000 | 4568 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2006 | 3848 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2000 | 3420 | 0.010 |
Why?
|
| RNA | 1 | 2000 | 2749 | 0.010 |
Why?
|
| Hospitalization | 1 | 2009 | 10262 | 0.010 |
Why?
|
| Pregnancy | 1 | 2008 | 29144 | 0.000 |
Why?
|